Table 1.

Neuroblastoma Patient Derived Xenograft Models Used in Repotrectinib Monotherapy Therapeutic Study

PDX Model	Sample Type for PDX Generation	Genomic Profile
		ALK Status	MYCN Status	Other relevant genomic aberrations1 (incl. chromosome 1p, 11q, 17q loss/gain)
MSKNBL-40352	Primary Resection	Amplified and R1275Q	Amplified	N/A
MSKNBL-12717	Metastatic Lesion at Primary Resection	ALK F1245I	WT	N/A
MSKNBL-30595	Metastatic Relapse	ALK F1174V	Amplified	TERT promoter mutation, TP53 R249S
MSKNBL-93255	Metastatic Relapse	ALK F1174L	Amplified	1p loss, 17q gain
MSKNBL-80717	Metastatic Relapse	ALK R1275Q	Amplified	1p loss
MSKNBL-47976	Metastatic Relapse	WT	Amplified	1p loss, 17q gain
MSKNBL-41817	Metastatic Relapse	WT	WT	11q gain, 17q gain
MSKNBL-82180	Metastatic Relapse	WT	WT	ATRX E553*, 17q gain

¹no PDX models were characterized by mutations in ROS1, NTRK1–3, JAK, FAK, or SRC genes; WT= wild type